Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RareStone Group
Shanghai, Shanghai, Chinalinkedin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RareStone Group has successfully commercialized pitolisant for narcolepsy in China—the first non-stimulant/non-addictive drug approved for this indication there. Other assets are at pre-NDA or earlier stages. The company previously held rights to setmelanotide but these were returned to Rhythm Pharmaceuticals in March 2025 after termination of their agreement.
- Therapeutic areas
- PulmonologyNeurologyEndocrinology
- Modalities
- Small moleculeMonoclonal antibodyPeptide
- Industry
- Biotech
02
Partnerships
BioprojetRhythm PharmaceuticalsTencentWorld Orphan Drug Alliance consortium
Beyond the preview
Go deeper on RareStone Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RareStone Group.